Want to see RFL full AI Analyst Report?
RFL Stock Chart & Stats
$2.24
$0.08(3.76%)
At close: 4:00 PM EDT
$2.24
$0.08(3.76%)
Day’s Range― - ―
52-Week Range$1.12 - $3.96
Previous CloseN/A
Volume22.68K
Average Volume (3M)106.27K
Market Cap
$133.67M
Enterprise Value$40.59
Total Cash (Recent Filing)$30.50M
Total Debt (Recent Filing)$610.00K
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding51,212,833
10 Day Avg. Volume126,987
30 Day Avg. Volume106,271
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.53
Price to Sales (P/S)54.22
P/FCF Ratio-2.63
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces refinancing pressure and interest burden, giving Rafael Holdings greater flexibility to fund biotechnology development and manage its real-estate interests while limiting balance-sheet risk.
Phase 3 And FDA ProgressCompleting the pivotal study and advancing FDA engagement are important steps toward potential commercialization of Trappsol Cyclo. Expanded access may also support patient access and generate experience ahead of regulatory decisions.
Expanded Biotechnology Intellectual PropertyAdditional exclusive intellectual property can strengthen Rafael’s strategic position in Alzheimer’s research, improve protection around future development programs, and broaden the long-term value of its life-sciences portfolio.
Bears Say
Small And Declining Revenue BaseVery low and declining revenue indicates that the operating platform has not yet established meaningful commercial scale. This limits internal funding capacity and leaves results highly dependent on future biotechnology milestones or asset monetization.
Persistent Cash BurnSustained negative operating and free cash flow means current activities are consuming capital rather than funding themselves. Even with low leverage, prolonged burn could reduce financial flexibility or require additional funding over time.
Deep Losses And Value ErosionLarge losses relative to the revenue base show that profitability remains distant and operating costs are not yet supported by commercial income. Negative returns and declining equity indicate continued erosion of shareholder value despite modest debt.
Rafael Holdings News
RFL FAQ
What was Rafael Holdings Inc’s price range in the past 12 months?
Rafael Holdings Inc lowest stock price was $1.12 and its highest was $3.96 in the past 12 months.
What is Rafael Holdings Inc’s market cap?
Rafael Holdings Inc’s market cap is $133.67M.
When is Rafael Holdings Inc’s upcoming earnings report date?
Rafael Holdings Inc’s upcoming earnings report date is Nov 02, 2026 which is in 61 days.
How were Rafael Holdings Inc’s earnings last quarter?
Rafael Holdings Inc released its earnings results on Jun 11, 2026. The company reported -$0.082 earnings per share for the quarter.
Is Rafael Holdings Inc overvalued?
According to Wall Street analysts Rafael Holdings Inc’s price is currently Overvalued.
Does Rafael Holdings Inc pay dividends?
Rafael Holdings Inc pays a Semiannually dividend of $0.02 which represents an annual dividend yield of N/A. See more information on Rafael Holdings Inc dividends here
What is Rafael Holdings Inc’s EPS estimate?
Rafael Holdings Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rafael Holdings Inc have?
Rafael Holdings Inc has 51,212,833 shares outstanding.
What happened to Rafael Holdings Inc’s price movement after its last earnings report?
Rafael Holdings Inc reported an EPS of -$0.082 in its last earnings report. Following the earnings report the stock price went up 19.101%.
Which hedge fund is a major shareholder of Rafael Holdings Inc?
Currently, no hedge funds are holding shares in RFL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rafael Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-14.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Rafael Holdings Inc
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Technical Analysis
Ownership Overview
30.79% Insiders
3.46% Mutual Funds
0.27% Other Institutional Investors
62.12% Public Companies and
Individual Investors